best biotech investments
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal - making it the fifth-largest biotech deal in history according to Standard & Poor's Capital IQ.
The Amgen deal with Onyx highlights where insiders - and investors - see the best investments in the biotech industry.
The Best Biotech Stocks for 2013 Are Now Within Your Reach
Biotech stocks are soaring in 2013 as major innovations in healthcare have offered enormous breakthroughs on once-untreatable diseases and conditions.
But for years, it was tricky to invest in some of today's best biotech companies given their volatility and uncertainty in the industry. For the better part of five years, some of today's leading biotech stocks remained essentially flat.
For some time, it was best to stick to large-scale pharmaceutical companies with a strong yield and avoid mass speculation in hit-or-miss penny stocks.
Well, not any more. Shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) - which tracks industry returns - are up a staggering 42% since the beginning of the year, and the health/biotech industry has the highest returns of any sector for the year.
And you haven't seen anything yet...
With one of the most exciting biotech companies now joining the NYSE and another setting its focus on an uplisting, we're seeing major changes in the biotech industry and investment. And there are companies poised to become the best biotech stocks you can find right now.
Best Investments: The One Stock to Buy in the Red-Hot Biotech Sector
For the best investments to add a little high-potential punch to your portfolio, nothing's better than biotech.
The iShares Nasdaq Biotechnology Exchange Traded Fund (ETF) (Nasdaq: IBB) rose 30.2% in the last 12 months and is already up a healthy 16.5% year to date.
In fact, the biotech sector has been a consistent performer for investors. The Nasdaq Biotechnology Index has notched 16.1% annualized returns for the last five years.
Big gains from just three stocks -- Amgen Inc. (Nasdaq: AMGN), BiogenIdec Inc. (Nasdaq: BIIB) and Gilead Sciences Inc. (Nasdaq: GILD) -- created a whopping $60 billion in combined shareholder gains in 2012.
And analysts expect the trend to continue.